孕11-14周子宫下段瘢痕评估筛查剖宫产术后胎盘植入谱系疾病
本研究前瞻性纳入有剖宫产史的孕妇,在孕11+0至13+6周经阴道超声评估子宫下段瘢痕位置与胎盘位置,将瘢痕位于宫颈峡部管上方且胎盘低置者定为高危。结果显示该方案筛查胎盘植入谱系疾病(PAS)的阴性预测值为100%,阳性似然比21.33, feasibility良好。
要点
- 孕11-14周经阴道超声可清晰显示79.9%剖宫产史孕妇的子宫下段瘢痕。
- 瘢痕位于宫颈峡部管上方且胎盘低置者PAS风险高,阴性预测值达100%。
- BMI≥30 kg/m2与瘢痕位于宫颈峡部管上方独立相关(OR 2.42)。
核心结论
- 孕11-14周经阴道超声评估子宫下段瘢痕位置与胎盘位置,可有效识别剖宫产史孕妇后续发生PAS disorder的风险。
- 胎盘植入于暴露的子宫下段瘢痕上方是预测PAS disorder的关键发现,阴性预测值极佳。
研究设计与样本
- 前瞻性验证研究,纳入535名有剖宫产史孕妇,在孕11+0至13+6周行经阴道超声评估子宫下段瘢痕。
- 采用标准化正中矢状面,包含宫颈峡部管、子宫瘢痕和胎盘部位,根据瘢痕大小和位置分为四组。
- 根据瘢痕位置与胎盘位置关系将孕妇分为PAS高危和低危,高危者于20周和28-30周随访。
主要发现
- 共502名同意检查,401名(79.9%)可显示子宫下段瘢痕。
- 瘢痕位于宫颈峡部管上方者占9.0%(36/401),其中仅5.7%(23/401)同时胎盘低置覆盖瘢痕。
- 23名高危孕妇中,2例在中孕期筛查发现PAS,1例在中孕期终止妊娠清宫时发现胎盘粘连。
- 94.3%(378/401)孕妇在早孕期筛查为PAS低危。
- 筛查方案阳性似然比21.33(95%CI 13.02-34.96),灵敏度100%(95%CI 29.24-100%),特异度95.31%(95%CI 92.39-97.35%),阳性预测值16.7%(95%CI 5.8-39.2%),阴性预测值100%(95%CI 98.4-100%)。
关键数值与推荐
- 高危定义:瘢痕位于宫颈峡部管上方且胎盘低置(胎盘覆盖暴露的瘢痕)。
- 低危定义:瘢痕位于宫颈峡部管内和/或胎盘位置高。
- 多变量回归显示仅 maternal BMI≥30 kg/m2 与瘢痕位于宫颈峡部管上方显著相关(OR 2.42,95%CI 1.04-5.39;P=0.03)。
- 既往择期临产前剖宫产与瘢痕位于宫颈峡部管上方风险有升高趋势(OR 1.72,95%CI 0.80-3.68),但无统计学显著性。
临床怎么用
- 对剖宫产史孕妇在孕11-14周常规行经阴道超声评估子宫下段瘢痕位置和胎盘位置,以筛查PAS风险。
- 发现瘢痕位于宫颈峡部管上方且胎盘低置者应列为高危,并在20周和28-30周随访。
- 筛查阴性者PAS风险极低,阴性预测值达100%,可有助于分层管理。
局限性
- 子宫下段瘢痕显示率为79.9%,部分孕妇无法完成评估。
- 高危组样本量小(23例),PAS结局事件少,阳性预测值置信区间宽。
- 研究为单中心前瞻性验证,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To validate prospectively transvaginal ultrasound assessment of the lower uterine segment (LUS) scar at the time of first-trimester screening in women with previous Cesarean section (CS) and to determine its feasibility and accuracy in stratifying women according to the risk for placenta accreta spectrum (PAS) disorder. METHODS: Women with a history of CS were recruited between 11 + 0 and 13 + 6 weeks' gestation and underwent LUS scar assessment using transvaginal ultrasound. A standardized midsagittal plane, which included the cervicoisthmic canal (CIC), the uterine scar and the placental site, was obtained. The scar was described in terms of its size (narrow or dehiscent) and its location in relation to the CIC (within or above), with each LUS scar classified into one of four groups based on these features. Placental location was assessed and classified as high- or low-lying. Women were stratified according to the risk of PAS, based on the relationship between the scar location and placental site. Women were considered high risk when the scar was above the CIC and the placenta was low-lying (i.e. when the placenta was overlying an exposed scar) and low risk when the scar was within the CIC and/or the placenta was high. High-risk patients were followed up at 20 weeks and 28-30 weeks for the development of PAS. Maternal demographics, detailed obstetric history and obstetric outcome were collected. RESULTS: First-trimester transvaginal ultrasound was offered to 535 women with prior CS during the study period. A LUS scar was visualized in 79.9% (401/502) of those who agreed to undergo the examination. At this scan, the LUS scar was above the CIC in 9.0% (36/401) of women, but only 5.7% (23/401) additionally had a low-lying placenta overlying the scar. Of these 23 high-risk women, two were found to have PAS on the mid-trimester screening scan and one was noted to have placental adherence during evacuation following mid-trimester termination of pregnancy. On the first-trimester scan, 94.3% (378/401) of women were at low risk of PAS. This screening protocol yielded a positive likelihood ratio of 21.33 (95% CI, 13.02-34.96), sensitivity of 100% (95% CI, 29.24-100%), specificity of 95.31% (95% CI, 92.39-97.35%), positive predictive value of 16.7% (95% CI, 5.8-39.2%) and negative predictive value of 100% (95% CI, 98.4-100%). On multivariable regression analysis performed to identify confounding variables associated with a LUS scar above the CIC, only maternal body mass index ≥ 30 kg/m2 was significant (odds ratio (OR), 2.42 (95% CI, 1.04-5.39); P = 0.03). Although there was a trend towards an increased risk of a LUS scar above the CIC in women with prior elective prelabor CS (OR, 1.72 (95% CI, 0.80-3.68)), this association did not reach statistical significance. CONCLUSIONS: Routine transvaginal ultrasound assessment of the location of the LUS scar and placenta at the time of first-trimester screening between 11 + 0 and 13 + 6 weeks' gestation in women with prior CS is a feasible and effective tool to identify those at risk of subsequent development of PAS disorder. A finding of placental implantation over an exposed LUS scar seems to be cardinal in predicting the risk of PAS disorder in women with prior CS, with an excellent negative predictive value. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bhatia A, Palacio M, Wright AM, et al. Lower uterine segment scar assessment at 11-14 weeks' gestation to screen for placenta accreta spectrum in women with prior Cesarean delivery. Ultrasound Obstet Gynecol. 2022. PMID: 34254386. doi:10.1002/uog.23734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。